FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety program requirements.
FDA Eases Rules For Bristol Myers’ Cell Therapies For Blood Cancers
Where Today's News Shapes Tomorrow
